Key takeaways
- A new retrospective study of 30 million health records links tirzepatide to higher rates of temporary hair loss (alopecia) than semaglutide.
- At 12 months, incident alopecia occurred in 4.20% of tirzepatide users compared to 2.88% of semaglutide users.
- The difference persists even when patients are matched for losing the same amount of weight, suggesting biological differences beyond rapid weight loss.
- Medical experts note that this hair loss is typically temporary telogen effluvium, which resolves once weight stabilizes.
What happened
A new pre-print study has revealed that patients taking tirzepatide (the active ingredient in Mounjaro and Zepbound) experience higher rates of temporary hair loss, or alopecia, compared to those taking semaglutide (the active ingredient in Ozempic and Wegovy).
The retrospective cohort study, conducted by researchers at nference Labs, analyzed electronic health records from a massive network of 30 million patients. Investigators tracked new users of both medications who had no prior history of alopecia over a 12-month period to determine how many developed new-onset hair shedding.
Why it matters
For patients choosing between semaglutide and tirzepatide, side effects play a massive role in the decision-making process. While gastrointestinal issues are widely discussed, hair thinning—known medically as telogen effluvium—is a major cosmetic and psychological concern for many buyers.
This data is highly significant for the growing number of Americans turning to cash-pay telehealth providers and compounding pharmacies for their weight-loss care. Because tirzepatide generally delivers greater overall weight loss than semaglutide, it has become highly sought after. However, this study suggests that buyers may need to weigh that superior efficacy against a statistically higher risk of noticeable hair shedding.
What the data says
The nference Labs study uncovered a clear, widening gap in hair loss rates between the two medications over time:
- At 6 months: Incident alopecia occurred in 1.55% of tirzepatide users compared to 1.24% of semaglutide users.
- At 12 months: The gap widened, with hair loss affecting 4.20% of tirzepatide users versus 2.88% of semaglutide users.
- Among female patients: The overall incidence of hair loss was even higher, reaching 5.44% for female tirzepatide users compared to 3.63% for female semaglutide users.
Crucially, the researchers adjusted the data to account for the speed and volume of weight loss. Rapid weight loss is a well-known trigger for temporary hair shedding. However, even when patients were matched for losing identical amounts of weight, tirzepatide users still had higher rates of hair loss (4.24%) than semaglutide users (3.33%).
Because this is a pre-print study, it has not yet undergone formal peer review. Clinical experts, including Dr. Mona Gohara, a clinical professor of dermatology at the Yale School of Medicine, caution that while these findings are important, they require further confirmation to establish an exact causal link.
How it compares
For US consumers comparing these options, the choice between semaglutide and tirzepatide often comes down to balancing cost, efficacy, and side effects.
- Efficacy vs. Side Effects: Tirzepatide is a dual GIP and GLP-1 receptor agonist, whereas semaglutide only targets GLP-1 receptors. This dual-action mechanism helps tirzepatide deliver higher average weight loss, but it may also alter the environment surrounding hair follicles differently, potentially explaining the higher alopecia rates.
- The Cost Factor: On the commercial market, name-brand Zepbound and Mounjaro carry a retail list price of over $1,000 per month, while Wegovy and Ozempic cost around $930 to $1,350.
- Telehealth and Compounded Alternatives: To bypass these high retail prices, many buyers use telehealth platforms to access compounded versions of these peptides. On average, compounded semaglutide ranges from $200 to $300 per month, while compounded tirzepatide is more complex to manufacture and typically costs $300 to $500 per month. US buyers must now decide if paying a premium for tirzepatide is worth both the extra cost and the higher statistical risk of hair thinning.
How this fits the bigger picture
This study adds to a growing body of clinical data examining the secondary side effects of GLP-1 therapies. As these medications shift from niche treatments to mainstream metabolic blockbusters, researchers are looking beyond standard stomach issues to study effects on skin, muscles, and bones. For instance, we have previously covered how companies are using specialized formulas to address cosmetic side effects like "Ozempic face" in our report on how /news/nestle-ai-glp1-side-effects-muscle-loss targets muscle and tissue changes.
Furthermore, understanding the nuance of these side effects is increasingly critical as the landscape of insurance coverage shifts. With major commercial insurers pulling back on coverage, as detailed in our analysis of how /news/insurers-restrict-glp1-coverage-weight-loss-telehealth-buyers drives patients to cash-pay options, consumers are spending their own money on these treatments. When paying out-of-pocket, buyers deserve complete transparency regarding the side-effect profiles of the molecules they are purchasing.
What happens next
As this pre-print research undergoes peer review, dermatologists emphasize that the hair shedding associated with GLP-1 medications is typically temporary. Telogen effluvium occurs when a physical stressor shocks hair follicles into a resting phase, but the follicles themselves are not permanently damaged. Once the body adapts to the medication and weight stabilizes, the hair cycle normally resets.
Patients currently experiencing persistent shedding, bald spots, scalp inflammation, or pain should consult a board-certified dermatologist. For those planning to start a weight-loss journey, discussing these risk profiles with a telehealth provider can help tailor a treatment plan that aligns with both your aesthetic goals and your metabolic needs.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication regimen.